YI-CHIH LINTAI-SHUAN LAIWu H.-Y.YU-HSIANG CHOUWEN-CHIH CHIANGSHUEI-LIONG LINYUNG-MING CHENTZONG-SHINN CHUYU-KANG TU2020-05-262020-05-2620200009-9236https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084426053&doi=10.1002%2fcpt.1859&partnerID=40&md5=d2b89b3eb8851e2b98eb97e55d50ca44https://scholars.lib.ntu.edu.tw/handle/123456789/494838The efficacy and safety of statin and ezetimibe combination therapy in patients with chronic kidney disease (CKD) remains unclear. To assess the effect of statin and ezetimibe combination therapy on controlling lipid profiles and reducing cardiovascular events in patients with CKD, we conducted a systematic review and meta-analysis. We selected randomized controlled trials comparing this combination therapy with statin monotherapy or placebo in patients with CKD from the PubMed, Embase, and Cochrane Central Register of Controlled Trials databases published before September 1, 2018 on the Internet. Eight articles on seven studies, with a total of 14,016 patients with CKD, were selected from 412 full-text articles. Statin and ezetimibe combination therapy had beneficial effects on serum total cholesterol (weighted mean difference (WMD) ?20.31?mg/dL, 95% confidence interval (CI), ?26.87 to ?13.75?mg/dL, P?<?0.001), low-density lipoprotein cholesterol (WMD ?17.22?mg/dL, 95% CI, ?18.93 to ?15.51?mg/dL, P?<?0.001), and triglycerides (WMD ?15.08?mg/dL, 95% CI, ?23.41 to ?6.75?mg/dL, P?<?0.001) compared with statin monotherapy. Statin and ezetimibe combination therapy significantly reduced all-cause mortality and major adverse cardiovascular events (risk ratio 0.86, 95% CI, 0.77 to 0.97, P?=?0.01). The incidence of adverse events was low, with no significant difference between statin and ezetimibe combination therapy and statin monotherapy. In conclusion, the statin and ezetimibe combination therapy significantly improved serum lipid profiles and reduced risks of all-cause deaths and major adverse cardiovascular events compared with the control group in patients with CKD. ? 2020 The Authors Clinical Pharmacology & Therapeutics ? 2020 American Society for Clinical Pharmacology and Therapeutics[SDGs]SDG3cholesterol; creatine kinase; ezetimibe; hydroxymethylglutaryl coenzyme A reductase inhibitor; lipid; low density lipoprotein cholesterol; triacylglycerol; biological marker; ezetimibe; hydroxymethylglutaryl coenzyme A reductase inhibitor; lipid; all cause mortality; Article; cardiovascular risk; cholesterol blood level; chronic kidney failure; drug effect; drug efficacy; drug safety; gastrointestinal symptom; hepatobiliary disease; human; incidence; lipid blood level; lipid fingerprinting; major adverse cardiac event; meta analysis; mortality risk; myopathy; priority journal; randomized controlled trial (topic); rhabdomyolysis; risk reduction; systematic review; triacylglycerol blood level; adult; aged; blood; cardiovascular disease; cause of death; chronic kidney failure; drug combination; dyslipidemia; female; kidney; male; middle aged; mortality; pathophysiology; patient safety; risk assessment; risk factor; time factor; treatment outcome; Adult; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Drug Combinations; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lipids; Male; Middle Aged; Patient Safety; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcomejournal article10.1002/cpt.1859323200582-s2.0-85084426053